Article(id=1326652229492257702, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652135099445330, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.09.016, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1736179200000, receivedDateStr=2025-01-07, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228139516, onlineDateStr=2026-11-09, pubDate=1757433600000, pubDateStr=2025-09-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228139516, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228139516, creator=13701087609, updateTime=1794228139516, updator=13701087609, issue=Issue{id=1326652135099445330, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='9', pageStart='869', pageEnd='998', issueExtLink='null', onlineDate='null', pubDate='1757433600000', pubDateStr='2025-09-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228117011, creator='13701087609', updateTime=1794272950571, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840181111501690, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652135099445330, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840181111501691, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652135099445330, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=972, endPage=977, ext={EN=ArticleExt(id=1326652229722944423, articleId=1326652229492257702, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress of the antifungal drug ibrexafungerp, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

With the increase of invasive fungal infections, the use of antifungal drug has become more frequently, and the emergence of fungal resistance has become an inevitable problem. Given the limited availability of existing antifungal drugs and their severe side effects, the United States Food and Drug Administration has approved a new antifungal drug, ibrexafungerp, which is a semi-synthetic chemical derivative of the natural product enfumafungin. It has broad-spectrum antibacterial activity, demonstrates strong antibacterial activity against Candida and Aspergillus, including those echinocandins- and azoles-resistant strains. It's currently used in the clinical treatment of vulvovaginal candidiasis. Ibrexafungerp has good oral bioavailability and tolerance, with few adverse reactions. It is a β-1, 3-glucan synthase inhibitor with a new structure and has a good prospect in the clinical treatment of invasive fungal infections. This article reviewed the research and development process, clinical research and drug interactions of ibrexafungerp.

, authors=Junyi WANG, Haodong CHEN, Jiawei TANG, Songbai YANG, Shaoxin CHEN*, authorsList=Junyi WANG, Haodong CHEN, Jiawei TANG, Songbai YANG, Shaoxin CHEN, authorCompany=null, correspAuthors=Shaoxin CHEN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652229970408360, articleId=1326652229492257702, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=抗真菌药物艾瑞芬净的临床研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

侵袭性真菌感染的增加导致抗真菌药物使用频率增高,真菌耐药性的出现成为不可避免的问题。在现有抗真菌药物有限且不良反应明显的情况下,美国食品药品监督管理局批准新型抗真菌药物艾瑞芬净上市,该药是天然产物英夫马芬净的化学半合成衍生物,具有广谱抗菌活性,对包括耐棘白菌素类、耐唑类药物在内的念珠菌和曲霉均具有较强的抗菌活性,目前临床多用于治疗外阴阴道念珠菌病。艾瑞芬净具有良好的口服生物利用度及耐受性,且不良反应少,是一种具有全新结构的β-1,3-葡聚糖合成酶抑制剂,在侵袭性真菌病感染的临床治疗中具有良好应用前景。该文主要对艾瑞芬净的研发过程、临床研究及药物相互作用等方面进行综述。

, authors=汪君怡, 陈浩东, 汤佳伟, 杨松柏, 陈少欣*, authorsList=汪君怡, 陈浩东, 汤佳伟, 杨松柏, 陈少欣, authorCompany=null, correspAuthors=陈少欣, authorNote=

汪君怡,硕士研究生,研究方向:丝状真菌的发酵。

, correspAuthorsNote=
陈少欣,研究员,生物部主任,研究方向:微生物药物及生物合成。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=xIm1MzG0ZinI4d/Bn/9xLQ==, magXml=hDsw8iREURwnWCmVealklQ==, pdfUrl=null, pdf=XvqwBKTZR5n7wZPWt6iUXw==, pdfFileSize=975628, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=uh6IoBVscGYaKvTVgU2xZQ==, mapNumber=null, fund=null)}, authors=[Author(id=1326652230264009645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230347895727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230264009645, language=EN, stringName=Junyi WANG, firstName=Junyi, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652230415004592, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230264009645, language=CN, stringName=汪君怡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio={"content":"

汪君怡,硕士研究生,研究方向:丝状真菌的发酵。

"}, bioImg=null, bioContent=

汪君怡,硕士研究生,研究方向:丝状真菌的发酵。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652230477919154, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230561805236, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230477919154, language=EN, stringName=Haodong CHEN, firstName=Haodong, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652230641497013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230477919154, language=CN, stringName=陈浩东, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652230708605879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230779909049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230708605879, language=EN, stringName=Jiawei TANG, firstName=Jiawei, middleName=null, lastName=TANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652230842823610, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230708605879, language=CN, stringName=汤佳伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652230914126780, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230989624254, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230914126780, language=EN, stringName=Songbai YANG, firstName=Songbai, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652231065121727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230914126780, language=CN, stringName=杨松柏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652231128036289, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652231195145155, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652231128036289, language=EN, stringName=Shaoxin CHEN, firstName=Shaoxin, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652231270642628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652231128036289, language=CN, stringName=陈少欣, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])])], keywords=[Keyword(id=1326652231358723013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, language=EN, orderNo=1, keyword=ibrexafungerp), Keyword(id=1326652231438414790, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, language=EN, orderNo=2, keyword=enfumafungin), Keyword(id=1326652231492940743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, language=EN, orderNo=3, keyword=vulvovaginal candidiasis), Keyword(id=1326652231560049608, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, language=CN, orderNo=1, keyword=艾瑞芬净), Keyword(id=1326652231627158473, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, language=CN, orderNo=2, keyword=英夫马芬净), Keyword(id=1326652231690073034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, language=CN, orderNo=3, keyword=外阴阴道念珠菌病)], refs=[Reference(id=1326652233543955405, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=MENDLING W, BRASCH J. Guideline vulvovaginal candidosis(2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society[J]. Mycoses, 2012, 55(Suppl 3): 1-13., articleTitle=null, refAbstract=null), Reference(id=1326652233623647182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=MARTIN LOPEZ JE. Candidiasis(vulvovaginal)[J]. Br Med J Clin Evid, 2015, 2015: 0815., articleTitle=null, refAbstract=null), Reference(id=1326652233694950351, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=WORKOWSKI KA, BACHMANN LH, CHAN PA, et al. Sexually transmitted diseases treatment guideline, 2021[J].MMWR Recomm Rep, 2021, 70(4): 1-187., articleTitle=null, refAbstract=null), Reference(id=1326652233791419344, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG FJ, ZHANG D, LIU ZH, et al. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China[J]. Chin Med J, 2016, 129(10): 1161-1165., articleTitle=null, refAbstract=null), Reference(id=1326652233866916817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=PFALLER MA, DIEKEMA DJ, GIBBS DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997—2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing[J]. J Clin Microbiol, 2009, 47(1): 117-123., articleTitle=null, refAbstract=null), Reference(id=1326652233921442770, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=范琳媛, 刘朝晖, 白会会, 等. 中国1 200株外阴阴道假丝酵母菌病致病菌对5种常用抗真菌药物的耐药性和敏感性分析[J]. 中华妇产科杂志, 2022, 57(8): 601-607., articleTitle=null, refAbstract=null), Reference(id=1326652233975968723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=SOBEL JD, SOBEL R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species[J]. Expert Opin Pharmacother, 2018, 19(9): 971-977., articleTitle=null, refAbstract=null), Reference(id=1326652234038883284, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Food and Drug Administration. Brexafemme(ibrexafungerp tablets), for oral use[EB/OL]. (2021-06-01)[2024-11-04]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1326652234101797845, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=PELAEZ F, CABELLO A, PLATAS G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms[J]. Syst Appl Microbiol, 2000, 23(3): 333-343., articleTitle=null, refAbstract=null), Reference(id=1326652234164712406, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=BILLS GERALD F, JAVIER C, PELAEZ F, et al. Hormonema carpetanum sp. nov., a new lineage of dothideaceous black yeasts from Spain[J]. Mycology, 2004,50(1): 149-157., articleTitle=null, refAbstract=null), Reference(id=1326652234223432663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHWARTZ RE, SMITH SK, ONISHI JC, et al. The isolation and structure determination of enfumafungin, a triterpene glycoside antifungal agent from the fermenation of a Hormonema sp[J]. J Am Chem Soc, 2000, 122: 4882-4886., articleTitle=null, refAbstract=null), Reference(id=1326652234286347224, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=谢秋萍, 卫腾云, 谢亚茹, 等. 产纽莫康定B0丝状真菌Filamentous fungus的菌种选育和发酵工艺优化[J]. 中国医药工业杂志, 2021, 52(5): 652-660., articleTitle=null, refAbstract=null), Reference(id=1326652234361844697, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=ALDEJOHANN AM, MENNER C, THIELEMANN N, et al. In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains[J]. Antimicrob Agents Chemother, 2024, 68(2): e0132423., articleTitle=null, refAbstract=null), Reference(id=1326652234424759258, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=JAMES MA, ROBERT RW, MARK LG, et al. Novel orally active inhibitors of β-1, 3-glucan synthesis derived from enfumafungin[J]. Bioorg Med Chem Lett, 2015, 25(24):5813-5818., articleTitle=null, refAbstract=null), Reference(id=1326652234504451035, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=JAMES MA, ROBERT RW, DANN LP Jr, et al. MK-5204:An orally active β-1, 3-glucan synthesis inhibitor[J]. Bioorg Med Chem Lett, 2020, 30(17): 127357., articleTitle=null, refAbstract=null), Reference(id=1326652234571559900, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=JAMES MA, ROBERT RW, DANN LP Jr, et al. Ibrexafungerp: an orally active β-1, 3-glucan synthesis inhibitor[J]. Bioorg Med Chem Lett, 2021, 32: 127661., articleTitle=null, refAbstract=null), Reference(id=1326652234634474461, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=PFALLER MA, MESSER SA, MOTYL MR, et al. In vitro activity of a new oral glucan synthase inhibitor(MK-3118)tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods[J]. Antimicrob Agents Chemother, 2013, 57(2): 1065-1068., articleTitle=null, refAbstract=null), Reference(id=1326652234714166238, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=JIMENEZ-ORTIGOSA C, PADERU P, MOTYL MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandinresistant Candida species and Aspergillus species isolates[J]. Antimicrob Agents Chemother, 2014, 58(2): 1248-1251., articleTitle=null, refAbstract=null), Reference(id=1326652234772886495, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=LEE A. Ibrexafungerp: first approval[J]. Drugs, 2021,81(12): 1445-1450., articleTitle=null, refAbstract=null), Reference(id=1326652234823218144, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=LARKIN EL, LONG L, ISHAM N, et al. A novel 1,3-β-D-glucan inhibitor, ibrexafungerp(formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis[J]. Antimicrob Agents Chemother, 2019,63(5): e02611-e02618., articleTitle=null, refAbstract=null), Reference(id=1326652234898715617, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU XY, ZHANG R, LI R, et al. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial[J]. Antimicrob Agents Chemother, 2023,67(12): e0107523., articleTitle=null, refAbstract=null), Reference(id=1326652234961630178, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=WRING S, MURPHY G, ATIEE G, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, asubstrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions[J]. J Clin Pharmacol, 2018,58(10): 1305-1313., articleTitle=null, refAbstract=null), Reference(id=1326652235020350435, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=WRING S, MURPHY G, ATIEE G, et al. Clinical pharmacokinetics and drug - drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus[J]. Clin Pharmacol Drug Dev, 2019,8(1): 60-69., articleTitle=null, refAbstract=null), Reference(id=1326652235100042212, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=ROMAN M, HERNANDEZ C, BLANCO D, et al. SCY-078 phase 2 study in moderate and severe vulvovaginal candidiasis[C]//27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria:European Congress of Clinical Microbiology and Infectious Diseases, 2017: 1748., articleTitle=null, refAbstract=null), Reference(id=1326652235162956773, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=SPEC A, PULLMAN J, THOMPSON GR, et al. MSG-10:A phase 2 study of oral ibrexafungerp(SCY-078) following initial echinocandin therapy in non-neutro-penic patients with invasive candidiasis[J]. J Antimicrob Chemother, 2019,74(10): 3056-3062., articleTitle=null, refAbstract=null), Reference(id=1326652235230065638, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=NYIRJESY P, SCHWEBKE JR, ANGULO DA, et al. Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis[J]. Clin Infect Dis, 2022, 74(12):2129-2135., articleTitle=null, refAbstract=null), Reference(id=1326652235326534631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=CADET APA, REBECCA BA, TUFA MMD, et al. A phase 2b, dose-finding study evaluating oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis(DOVE)[J]. Obstetr Gynecol, 2019, 133(1): 113S-114S., articleTitle=null, refAbstract=null), Reference(id=1326652235410420712, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHWEBKE JR, SOBEL R, GERSTEN JK, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial(VANISH 303)[J]. Clin Infect Dis, 2022, 74(11): 1979-1985., articleTitle=null, refAbstract=null), Reference(id=1326652235481723881, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=SOBEL R, NYIRJESY P, GHANNOUM MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study(VANISH 306)[J].BJOG, 2022, 129(3): 412-420., articleTitle=null, refAbstract=null), Reference(id=1326652235548832746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM K, JOHNSON JA, DERENDORF H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms[J]. J Clin Pharmacol, 2004, 44(10): 1083-1105., articleTitle=null, refAbstract=null), Reference(id=1326652235628524523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=OLAFUYI O, PAREKH N, WRIGHT J, et al. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?[J]. Pharmacol Res Perspect, 2021, 9(6): e00890., articleTitle=null, refAbstract=null), Reference(id=1326652235687244780, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG XQ, WANG WY, LI JJ, et al. Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase Ⅲ, randomized, double-blind study[J]. Infection, 2024, 52(5): 1787-1797., articleTitle=null, refAbstract=null), Reference(id=1326652235745965037, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=GHANNOUM M, ARENDRUP MC, CHATURVEDI VP, et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections[J]. Antibiotics, 2020, 9(9): 539., articleTitle=null, refAbstract=null), Reference(id=1326652235804685294, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=SCYNEXIS. SCYNEXIS Announces FDA approval of second indication for BREXAFEMME(ibrexafungerp tablets) for reduction in incidence of recurrent vulvovaginal candidiasis[EB/OL]. (2021-06-01)[2024-11-04]. https://ir.scynexis.com/news-events/press-releases/detail/314/scynexis-announces-fda-approval-of-second-indication-for., articleTitle=null, refAbstract=null), Reference(id=1326652235905348591, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=SEILER, GT, OSTROSKY-ZEICHNER L. Investigational agents for the treatment of resistant yeasts and molds[J]. Curr Fungal Infect Rep, 2021, 15(3): 104-115., articleTitle=null, refAbstract=null), Reference(id=1326652235964068848, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=SCYNEXIS. SCYNEXIS presents interim analysis from FURI at virtual IDWeek 2021 showing favorable therapeutic response in severe hospital-based fungal infections treated with oral ibrexafungerp[EB/OL]. (2021-06-01)[2024-11-04]. https://ir.scynexis.com/news-events/press-releases/detail/254/scynexis-presents-interim-analysis-from-furi-at-virtual., articleTitle=null, refAbstract=null)], funds=[Fund(id=1326652231786542027, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, awardId=2021YFC2102100, language=CN, fundingSource=科技部国家重点研发计划“绿色生物制造”项目(2021YFC2102100), fundOrder=null, country=null), Fund(id=1326652231853650892, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, awardId=23YF1445800, language=CN, fundingSource=上海启明星培育(扬帆专项)项目(23YF1445800), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.09.016, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.09.016, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.09.016, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.09.016, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1757433600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
抗真菌药物艾瑞芬净的临床研究进展
汪君怡 , 陈浩东 , 汤佳伟 , 杨松柏 , 陈少欣 *
世界临床药物 | 综述评论 2025,46(9): 972-977
收起
收藏切换
世界临床药物 |综述评论 2025 , 46 (9) : 972 -977
抗真菌药物艾瑞芬净的临床研究进展
全屏
[Author(id=1326652230264009645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230347895727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230264009645, language=EN, stringName=Junyi WANG, firstName=Junyi, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652230415004592, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230264009645, language=CN, stringName=汪君怡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio={"content":"

汪君怡,硕士研究生,研究方向:丝状真菌的发酵。

"}, bioImg=null, bioContent=

汪君怡,硕士研究生,研究方向:丝状真菌的发酵。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652230477919154, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230561805236, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230477919154, language=EN, stringName=Haodong CHEN, firstName=Haodong, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652230641497013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230477919154, language=CN, stringName=陈浩东, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652230708605879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230779909049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230708605879, language=EN, stringName=Jiawei TANG, firstName=Jiawei, middleName=null, lastName=TANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652230842823610, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230708605879, language=CN, stringName=汤佳伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652230914126780, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652230989624254, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230914126780, language=EN, stringName=Songbai YANG, firstName=Songbai, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652231065121727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652230914126780, language=CN, stringName=杨松柏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1326652231128036289, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652231195145155, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652231128036289, language=EN, stringName=Shaoxin CHEN, firstName=Shaoxin, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652231270642628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, authorId=1326652231128036289, language=CN, stringName=陈少欣, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652230180123561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, xref=null, ext=[AuthorCompanyExt(id=1326652230188512170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China), AuthorCompanyExt(id=1326652230201095083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652229492257702, companyId=1326652230180123561, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])])]
汪君怡, 陈浩东, 汤佳伟, 杨松柏, 陈少欣*
作者信息
  • 中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203
通讯作者:
陈少欣,研究员,生物部主任,研究方向:微生物药物及生物合成。
作者简介:

汪君怡,硕士研究生,研究方向:丝状真菌的发酵。

Clinical research progress of the antifungal drug ibrexafungerp
Junyi WANG, Haodong CHEN, Jiawei TANG, Songbai YANG, Shaoxin CHEN*
Affiliations
  • China state Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, National Key Laboratory of Lead Druggability Research, Shanghai 201203, China
出版时间: 2025-09-10 doi: 10.13683/j.wph.2025.09.016
文章导航
收藏切换

侵袭性真菌感染的增加导致抗真菌药物使用频率增高,真菌耐药性的出现成为不可避免的问题。在现有抗真菌药物有限且不良反应明显的情况下,美国食品药品监督管理局批准新型抗真菌药物艾瑞芬净上市,该药是天然产物英夫马芬净的化学半合成衍生物,具有广谱抗菌活性,对包括耐棘白菌素类、耐唑类药物在内的念珠菌和曲霉均具有较强的抗菌活性,目前临床多用于治疗外阴阴道念珠菌病。艾瑞芬净具有良好的口服生物利用度及耐受性,且不良反应少,是一种具有全新结构的β-1,3-葡聚糖合成酶抑制剂,在侵袭性真菌病感染的临床治疗中具有良好应用前景。该文主要对艾瑞芬净的研发过程、临床研究及药物相互作用等方面进行综述。

艾瑞芬净  /  英夫马芬净  /  外阴阴道念珠菌病

With the increase of invasive fungal infections, the use of antifungal drug has become more frequently, and the emergence of fungal resistance has become an inevitable problem. Given the limited availability of existing antifungal drugs and their severe side effects, the United States Food and Drug Administration has approved a new antifungal drug, ibrexafungerp, which is a semi-synthetic chemical derivative of the natural product enfumafungin. It has broad-spectrum antibacterial activity, demonstrates strong antibacterial activity against Candida and Aspergillus, including those echinocandins- and azoles-resistant strains. It's currently used in the clinical treatment of vulvovaginal candidiasis. Ibrexafungerp has good oral bioavailability and tolerance, with few adverse reactions. It is a β-1, 3-glucan synthase inhibitor with a new structure and has a good prospect in the clinical treatment of invasive fungal infections. This article reviewed the research and development process, clinical research and drug interactions of ibrexafungerp.

ibrexafungerp  /  enfumafungin  /  vulvovaginal candidiasis
汪君怡, 陈浩东, 汤佳伟, 杨松柏, 陈少欣. 抗真菌药物艾瑞芬净的临床研究进展. 世界临床药物, 2025 , 46 (9) : 972 -977 . DOI: 10.13683/j.wph.2025.09.016
Junyi WANG, Haodong CHEN, Jiawei TANG, Songbai YANG, Shaoxin CHEN. Clinical research progress of the antifungal drug ibrexafungerp[J]. World Clinical Drug, 2025 , 46 (9) : 972 -977 . DOI: 10.13683/j.wph.2025.09.016
  • 科技部国家重点研发计划“绿色生物制造”项目(2021YFC2102100)
  • 上海启明星培育(扬帆专项)项目(23YF1445800)
参考文献 引证文献
排序方式:
[1]
MENDLING W, BRASCH J. Guideline vulvovaginal candidosis(2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society[J]. Mycoses, 2012, 55(Suppl 3): 1-13.
[2]
MARTIN LOPEZ JE. Candidiasis(vulvovaginal)[J]. Br Med J Clin Evid, 2015, 2015: 0815.
[3]
WORKOWSKI KA, BACHMANN LH, CHAN PA, et al. Sexually transmitted diseases treatment guideline, 2021[J].MMWR Recomm Rep, 2021, 70(4): 1-187.
[4]
WANG FJ, ZHANG D, LIU ZH, et al. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China[J]. Chin Med J, 2016, 129(10): 1161-1165.
[5]
PFALLER MA, DIEKEMA DJ, GIBBS DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997—2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing[J]. J Clin Microbiol, 2009, 47(1): 117-123.
[6]
范琳媛, 刘朝晖, 白会会, 等. 中国1 200株外阴阴道假丝酵母菌病致病菌对5种常用抗真菌药物的耐药性和敏感性分析[J]. 中华妇产科杂志, 2022, 57(8): 601-607.
[7]
SOBEL JD, SOBEL R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species[J]. Expert Opin Pharmacother, 2018, 19(9): 971-977.
[8]
Food and Drug Administration. Brexafemme(ibrexafungerp tablets), for oral use[EB/OL]. (2021-06-01)[2024-11-04]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf.
[9]
PELAEZ F, CABELLO A, PLATAS G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms[J]. Syst Appl Microbiol, 2000, 23(3): 333-343.
[10]
BILLS GERALD F, JAVIER C, PELAEZ F, et al. Hormonema carpetanum sp. nov., a new lineage of dothideaceous black yeasts from Spain[J]. Mycology, 2004,50(1): 149-157.
[11]
SCHWARTZ RE, SMITH SK, ONISHI JC, et al. The isolation and structure determination of enfumafungin, a triterpene glycoside antifungal agent from the fermenation of a Hormonema sp[J]. J Am Chem Soc, 2000, 122: 4882-4886.
[12]
谢秋萍, 卫腾云, 谢亚茹, 等. 产纽莫康定B0丝状真菌Filamentous fungus的菌种选育和发酵工艺优化[J]. 中国医药工业杂志, 2021, 52(5): 652-660.
[13]
ALDEJOHANN AM, MENNER C, THIELEMANN N, et al. In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains[J]. Antimicrob Agents Chemother, 2024, 68(2): e0132423.
[14]
JAMES MA, ROBERT RW, MARK LG, et al. Novel orally active inhibitors of β-1, 3-glucan synthesis derived from enfumafungin[J]. Bioorg Med Chem Lett, 2015, 25(24):5813-5818.
[15]
JAMES MA, ROBERT RW, DANN LP Jr, et al. MK-5204:An orally active β-1, 3-glucan synthesis inhibitor[J]. Bioorg Med Chem Lett, 2020, 30(17): 127357.
[16]
JAMES MA, ROBERT RW, DANN LP Jr, et al. Ibrexafungerp: an orally active β-1, 3-glucan synthesis inhibitor[J]. Bioorg Med Chem Lett, 2021, 32: 127661.
[17]
PFALLER MA, MESSER SA, MOTYL MR, et al. In vitro activity of a new oral glucan synthase inhibitor(MK-3118)tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods[J]. Antimicrob Agents Chemother, 2013, 57(2): 1065-1068.
[18]
JIMENEZ-ORTIGOSA C, PADERU P, MOTYL MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandinresistant Candida species and Aspergillus species isolates[J]. Antimicrob Agents Chemother, 2014, 58(2): 1248-1251.
[19]
LEE A. Ibrexafungerp: first approval[J]. Drugs, 2021,81(12): 1445-1450.
[20]
LARKIN EL, LONG L, ISHAM N, et al. A novel 1,3-β-D-glucan inhibitor, ibrexafungerp(formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis[J]. Antimicrob Agents Chemother, 2019,63(5): e02611-e02618.
[21]
LIU XY, ZHANG R, LI R, et al. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial[J]. Antimicrob Agents Chemother, 2023,67(12): e0107523.
[22]
WRING S, MURPHY G, ATIEE G, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, asubstrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions[J]. J Clin Pharmacol, 2018,58(10): 1305-1313.
[23]
WRING S, MURPHY G, ATIEE G, et al. Clinical pharmacokinetics and drug - drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus[J]. Clin Pharmacol Drug Dev, 2019,8(1): 60-69.
[24]
ROMAN M, HERNANDEZ C, BLANCO D, et al. SCY-078 phase 2 study in moderate and severe vulvovaginal candidiasis[C]//27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria:European Congress of Clinical Microbiology and Infectious Diseases, 2017: 1748.
[25]
SPEC A, PULLMAN J, THOMPSON GR, et al. MSG-10:A phase 2 study of oral ibrexafungerp(SCY-078) following initial echinocandin therapy in non-neutro-penic patients with invasive candidiasis[J]. J Antimicrob Chemother, 2019,74(10): 3056-3062.
[26]
NYIRJESY P, SCHWEBKE JR, ANGULO DA, et al. Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis[J]. Clin Infect Dis, 2022, 74(12):2129-2135.
[27]
CADET APA, REBECCA BA, TUFA MMD, et al. A phase 2b, dose-finding study evaluating oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis(DOVE)[J]. Obstetr Gynecol, 2019, 133(1): 113S-114S.
[28]
SCHWEBKE JR, SOBEL R, GERSTEN JK, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial(VANISH 303)[J]. Clin Infect Dis, 2022, 74(11): 1979-1985.
[29]
SOBEL R, NYIRJESY P, GHANNOUM MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study(VANISH 306)[J].BJOG, 2022, 129(3): 412-420.
[30]
KIM K, JOHNSON JA, DERENDORF H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms[J]. J Clin Pharmacol, 2004, 44(10): 1083-1105.
[31]
OLAFUYI O, PAREKH N, WRIGHT J, et al. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?[J]. Pharmacol Res Perspect, 2021, 9(6): e00890.
[32]
WANG XQ, WANG WY, LI JJ, et al. Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase Ⅲ, randomized, double-blind study[J]. Infection, 2024, 52(5): 1787-1797.
[33]
GHANNOUM M, ARENDRUP MC, CHATURVEDI VP, et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections[J]. Antibiotics, 2020, 9(9): 539.
[34]
SCYNEXIS. SCYNEXIS Announces FDA approval of second indication for BREXAFEMME(ibrexafungerp tablets) for reduction in incidence of recurrent vulvovaginal candidiasis[EB/OL]. (2021-06-01)[2024-11-04]. https://ir.scynexis.com/news-events/press-releases/detail/314/scynexis-announces-fda-approval-of-second-indication-for.
[35]
SEILER, GT, OSTROSKY-ZEICHNER L. Investigational agents for the treatment of resistant yeasts and molds[J]. Curr Fungal Infect Rep, 2021, 15(3): 104-115.
[36]
SCYNEXIS. SCYNEXIS presents interim analysis from FURI at virtual IDWeek 2021 showing favorable therapeutic response in severe hospital-based fungal infections treated with oral ibrexafungerp[EB/OL]. (2021-06-01)[2024-11-04]. https://ir.scynexis.com/news-events/press-releases/detail/254/scynexis-presents-interim-analysis-from-furi-at-virtual.
2025年第46卷第9期
55
12
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.09.016
  • 接收时间:2025-01-07
  • 首发时间:2026-11-09
  • 出版时间:2025-09-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-01-07
基金
科技部国家重点研发计划“绿色生物制造”项目(2021YFC2102100)
上海启明星培育(扬帆专项)项目(23YF1445800)
作者信息
    中国医药工业研究总院,上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203

通讯作者:

陈少欣,研究员,生物部主任,研究方向:微生物药物及生物合成。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.09.016
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏